Urotensin II receptor expression in prostate cancer patients: A new possible marker

Abstract

Background: Urotensin II receptor has been poorly studied in prostate cancer. To evaluate the expression of urotensin II receptor (UII-R) in patients undergoing radical prostatectomy.Methods: Overall, we identified 140 patients treated with retropubic radical prostatectomy (RP) in one center. UII-R was evaluated in prostate biopsies with immunohistochemical staining, resulting in a granular cytoplasmic positivity, through automated system using the kit Urotensin II Receptor Detection System provided by Pharmabullet srl. Immunostained slides were independently and blindly evaluated by ten uro-pathologists. To evaluate UTII-R expression three different parameters were considered: localization, granules dimensions and intensity of expression. A score from 0 to 3 was applied to each parameter to obtain a score from 0 to 9. Each parameter and the total score were evaluated as predictors of high grade disease on surgical pathology and of advanced stage disease. Accuracy of total score for the prediction of upgrading and upstaging was analyzed using receiver operator characteristics curve and decision curve analysis (DCA).Results: On radical prostatectomy 92/140 (66%) presented high grade disease on surgical pathology. Patients with high grade disease presented an apical distribution of the receptor, larger granules and a more intense expression when compared to patients with low grade disease. A well they presented a higher total score. Subscores and total scores were found to be predictors of upgrading and upstaging. On ROC analysis total score presented an AUC of 0.72 and 0.70, respectively, for the prediction of upgrading and upstaging. On DCA total score showed a clinical benefit in the prediction of adverse pathological outcomes.Conclusion: Urotensin II receptor is a potential marker of adverse pathological outcomes. Further studies should confirm our data and evaluate its role as a prognostic marker. K E Y W O R D S accuracy, upgrading, upstaging, urotensin 288 |

Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82

“…UTS2D codes for urotensin 2 (UTS2), a vasoconstrictor that binds to urotensin 2 receptor (UTS2R) in the G protein coupled receptor (GPCR) pathway. In prostate cancer, two studies showed an association of lower UTS2R expression with higher Gleason score and a more advanced cancer stage [72,73], while a recent study demonstrated the opposite results i.e., a higher UTS2R expression correlated with higher grade and cancer stage [74]. In PC3 cells that have lower CD82 expression (PC3-5 V -CD82), although we did not find significant changes in UTS2R, we detected significantly higher UTS2D gene expression when compared with the +CD82 cells.…”

Development of an immune-related gene prognostic risk model and identification of an Immune infiltration signature in the tumor microenvironment of colon cancer

“…ESM1 is overexpressed in non-small cell lung cancer, clear cell renal cell carcinoma and ovarian cancer, to regulate tumor progression. Urotensin II (UTS2) [27] regulates vasoconstriction and is associated with a range of diseases with abnormal blood pressure regulation (e.g. hypertension, kidney disease, cirrhosis, etc.).…”

Prognostic Model of Colorectal Cancer Constructed by Eight Immune-Related Genes

“…Compared with normal tissues, UTS2, UCN, IL1RL2, and ESM1 are upregulated in CRC tissues. UTS2 (Urotensin-II) is a somatostatin-like cyclic heptapeptide (Kim et al, 2017) and participates in the occurrence of different cancers, especially colon, breast, and prostate cancers (Giulianelli et al, 2019). It is extensively expressed in vascular endothelial cells and various tissues such as the small intestine, colon, brain, heart, spleen, aorta, and so on (Yumrutas et al, 2015).…”